Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print          Annual reports

Thursday 06 May, 2021

GlaxoSmithKline PLC

Board and Committee Changes

RNS Number : 8440X
GlaxoSmithKline PLC
06 May 2021
 

 

GlaxoSmithKline plc

 

GSK announces changes to its Board and Committees

 

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

 

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

 

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee. 

 

Note

 

1.

From 6 May 2021 the Board of GSK comprises

 


Sir Jonathan Symonds 

Emma Walmsley   

Iain Mackay   

Dr Hal Barron  

Vindi Banga  

Charles Bancroft

Dr Anne Beal

Dr Vivienne Cox   

Lynn Elsenhans 

Dr Jesse Goodman   

Dr Laurie Glimcher   

Urs Rohner   

Non-Executive Chairman

Chief Executive Officer

Chief Financial Officer

Chief Scientific Officer and President, R&D

Senior Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

Independent Non-Executive Director

 

 

V A Whyte

Company Secretary

 

6 May 2021

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABLGDUCSGDGBL

a d v e r t i s e m e n t